checkAd
    Startseite > Aktien > Denali Therapeutics > Nachrichten
    Denali Therapeutics Aktie
    21,310
     
    USD
    -2,47 %
    -0,540 USD
    Letzter Kurs 22:30:00 Nasdaq
    21,270
     
    USD
    6.400 STK
    Geldkurs 22:02:00
    21,290
     
    USD
    100 STK
    Briefkurs 22:02:00
    ISIN: US24823R1059 · WKN: A2H9G8 · SYM: DNLI · USA

    Neueste Nachrichten

    Denali Therapeutics Announces FDA Has Selected DNL126 (ETV: SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
    03.06.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    07.05.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
    01.05.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    27.02.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces $500 million Private Placement Equity Financing
    27.02.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium
    07.02.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium
    01.02.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
    08.01.24 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
    30.08.23 · globenewswire · Denali Therapeutics
    Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
    08.08.23 · globenewswire · Denali Therapeutics
    Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV: IDS) Treatment in MPS II (Hunter Syndrome)
    20.06.23 · globenewswire · Denali Therapeutics